Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 14, 2021The Lancet Global HealthOpen Access

BCG re-vaccination in Malawi: 30-year follow-up of a large, randomised, double-blind, placebo-controlled trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JGJudith R. GlynnTeagasc - The Irish Agriculture and Food Development AuthorityKFKatherine FieldingUniversity of the WitwatersrandTMThemba MzembeAfrican Institute for Development Policy

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Glynn et al. (2021) studied this question.

synapsesocial.com/papers/6aa8a58f6d3963fac5080060https://doi.org/10.1016/s2214-109x(21)00309-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prevention of <i>M. tuberculosis</i> Infection with H4:IC31 Vaccine or BCG Revaccination2018 · 673 citations
  2. 2Protection by BCG Vaccine Against Tuberculosis: A Systematic Review of Randomized Controlled Trials2013 · 1,021 citations
  3. 3Large-scale whole genome sequencing of M. tuberculosis provides insights into transmission in a high prevalence area2015 · 274 citations
  4. 4Protective Effect of BCG against Tuberculous Meningitis and Miliary Tuberculosis: A Meta-Analysis1993 · 658 citations
  5. 5Changes in Mycobacterium tuberculosis Genotype Families Over 20 Years in a Population-Based Study in Northern Malawi2010 · 31 citations